Drug Discovery 플랫폼 시장 규모, 점유율 및 동향 분석 보고서 : 약제 유형별, 용도별, 치료 영역별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Drug Discovery Platforms Market Summary

The global drug discovery platforms market size was estimated at USD 3.4 billion in 2025 and is projected to reach USD 10.5 billion by 2033, growing at a CAGR of 15.1% from 2026 to 2033. The market growth is driven by several factors, including the increasing adoption of artificial intelligence (AI) and machine learning in drug discovery, rising pharmaceutical and biotechnology R&D investments, growing demand for precision medicine and targeted therapies, and advances in computational drug discovery.

The increasing adoption of AI and Machine Learning (ML) in drug discovery workflows is significantly driving the growth of the market. AI and ML-based platforms enable pharmaceutical and biotechnology companies to analyze large biological datasets, identify potential drug targets, and optimize lead compounds with greater speed and accuracy compared to conventional methods. These technologies support virtual screening, predictive toxicology, molecular modeling, and generative drug design, thereby reducing R&D costs and the time to molecule discovery.

In addition, AI-driven automation reduces clinical trial failure risks and improves decision-making efficiency. The growing demand for faster development of novel therapeutics, such as oncology and rare diseases, is further encouraging the adoption of AI-powered drug discovery platforms across the pharmaceutical industry. For instance, in January 2026, Pierre Fabre Laboratories and Iktos announced a collaboration for AI-driven drug discovery, aimed at developing novel small-molecule oncology therapies by combining computational design, biology, medicinal chemistry, medical science, and preclinical development capabilities.

This collaboration with Iktos marks an important milestone in our journey to build an AI-powered R&D engine at Pierre Fabre Laboratories. By integrating Iktos' generative AI and automated chemistry technologies into our research platforms, we are taking a step toward realizing our data and AI strategy. This cooperation exemplifies our ambition to leverage cutting-edge innovation to improve the quality and probability of success in drug discovery, while accelerating the delivery of meaningful advances for patients in oncology.

Audrey Kauffmann, Head of Data Science and Biometry at Pierre Fabre Medical Care R&D

Moreover, the rising demand for precision medicine and targeted therapies supports the growth of the drug discovery platforms market. Precision medicine develops treatments tailored to individual genetic profiles, biomarkers, and disease characteristics. This increases the adoption of AI-enabled drug discovery, genomics, bioinformatics, and multiomics technologies.

Drug discovery platforms support biomarker identification, molecular profiling, and patient stratification. This enables the development of highly targeted and effective therapies for diseases such as cancer, rare disorders, and neurological conditions. Consequently, pharmaceutical and biotechnology companies are increasingly investing in and collaborating on precision medicine-based drug development, supporting market growth. For instance, in March 2025, BostonGene Corporation announced a collaboration with Johnson & Johnson to evaluate biomarkers for colorectal cancer and multiple myeloma using AI-driven molecular profiling in clinical trials.

Similarly, in August 2024, BostonGene Corporation partnered with Takeda Pharmaceutical to evaluate immunotherapies using AI-powered molecular and immune profiling technologies. The collaboration focuses on improving patient selection, identifying predictive biomarkers for treatment response and toxicity, and enhancing clinical trial design through advanced multiomics and bioinformatics analysis. These partnerships aim to enhance patient stratification, optimize treatment selection, and identify predictive biomarkers through advanced molecular analytics.

Global Drug Discovery Platforms Market Report Segmentation

This report forecasts revenue growth and provides at the global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global drug discovery platforms market report based on drug type, application, therapeutic area, end use, and region:

• Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
• Small Molecule
• Large Molecule
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Target Identification
• Target Validation
• Lead Discovery
• Lead Optimization
• Preclinical Testing
• Other (including Clinical Trials)
• Therapeutic Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Neurology
• Cardiovascular Diseases
• Infectious and Immune System Diseases
• Digestive System Diseases
• Other (Respiratory Diseases, Diabetes)
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Biopharmaceutical Companies
• Academic and Research Institutes
• CROs/CDMO
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Drug Type Segment
  • 1.1.2. Application Segment
  • 1.1.3. Therapeutic Area Segment
  • 1.1.4. End Use Segment
  • 1.1.5. Regional scope
  • 1.1.6. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
    • 1.3.5.1. Data for primary interviews in North America
    • 1.3.5.2. Data for primary interviews in Europe
    • 1.3.5.3. Data for primary interviews in Asia Pacific
    • 1.3.5.4. Data for primary interviews in Latin America
    • 1.3.5.5. Data for Primary interviews in MEA
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives
  • 1.9.1. Objective 1
  • 1.9.2. Objective 2
  • 1.9.3. Objective 3

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug Type Outlook
  • 2.2.2. Application Outlook
  • 2.2.3. Therapeutic Area Segment
  • 2.2.4. End Use Outlook
  • 2.2.5. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Drug Discovery Platforms Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Industry Value Chain Analysis
  • 3.2.1. Reimbursement framework
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
    • 3.3.1.1. Increasing adoption of Artificial Intelligence (AI) and Machine Learning in drug discovery workflows
    • 3.3.1.2. Rising pharmaceutical and biotechnology R&D investments
    • 3.3.1.3. Growing demand for precision medicine and targeted therapies
  • 3.3.2. Market Restraint Analysis
    • 3.3.2.1. High implementation and operational costs of advanced drug discovery platforms
    • 3.3.2.2. Data privacy, integration, and regulatory challenges associated with AI-driven drug discovery systems
  • 3.3.3. Market Opportunity Analysis
  • 3.3.4. Industry Challenge
• 3.4. Application Overview
  • 3.4.1. Virtual Reality (VR) and Augmented Reality (AR)
  • 3.4.2. Artificial Intelligence (AI)
  • 3.4.3. Gamification
  • 3.4.4. Use of Multidisciplinary Approach in the Development of Simulators
  • 3.4.5. 3D Printing
• 3.5. Drug Discovery Platforms Market Analysis Tools
  • 3.5.1. Industry Analysis - Porter's
    • 3.5.1.1. Supplier power
    • 3.5.1.2. Buyer power
    • 3.5.1.3. Substitution threat
    • 3.5.1.4. Threat of new entrant
    • 3.5.1.5. Competitive rivalry
  • 3.5.2. PESTEL Analysis
    • 3.5.2.1. Political landscape
    • 3.5.2.2. Technological landscape
    • 3.5.2.3. Social landscape
    • 3.5.2.4. Economic landscape
    • 3.5.2.5. Legal landscape

Chapter 4. Drug Discovery Platforms Market: Drug Type Estimates & Trend Analysis

• 4.1. Drug Type Market Share, 2025 & 2033
• 4.2. Segment Dashboard
• 4.3. Global Drug Discovery Platforms Market by Drug Type Outlook
• 4.4. Small Molecule
  • 4.4.1. Small molecule market, 2021 - 2033 (USD Million)
• 4.5. Large Molecule
  • 4.5.1. Large molecule market, 2021 - 2033 (USD Million)

Chapter 5. Drug Discovery Platforms Market: Application Estimates & Trend Analysis

• 5.1. Application Market Share, 2025 & 2033
• 5.2. Segment Dashboard
• 5.3. Global Drug Discovery Platforms Market by Application Outlook
• 5.4. Target Identification
  • 5.4.1. Target identification market estimates and forecast 2021 to 2033 (USD Million)
• 5.5. Target Validation
  • 5.5.1. Target validation market estimates and forecast 2021 to 2033 (USD Million)
• 5.6. Lead Discovery
  • 5.6.1. Lead discovery market estimates and forecast 2021 to 2033 (USD Million)
• 5.7. Lead Optimization
  • 5.7.1. Lead optimization market estimates and forecast 2021 to 2033 (USD Million)
• 5.8. Preclinical Testing
  • 5.8.1. Preclnical tasting market estimates and forecast 2021 to 2033 (USD Million)
• 5.9. Other (including Clinical Trials)
  • 5.9.1. Other (including clinical trial) market estimates and forecast 2021 to 2033 (USD Million)

Chapter 6. Drug Discovery Platforms Market: Therapeutic Area Estimates & Trend Analysis

• 6.1. Therapeutic Area Market Share, 2025 & 2033
• 6.2. Segment Dashboard
• 6.3. Global Drug Discovery Platforms Market by Therapeutic Area Outlook
• 6.4. Oncology
  • 6.4.1. Oncology market estimates and forecast 2021 to 2033 (USD Million)
• 6.5. Neurology
  • 6.5.1. Neurology market estimates and forecast 2021 to 2033 (USD Million)
• 6.6. Cardiovascular Diseases
  • 6.6.1. Cardiovascular Diseases market estimates and forecast 2021 to 2033 (USD Million)
• 6.7. Infectious and Immune System Diseases
  • 6.7.1. Infectious and immune system diseases market estimates and forecast 2021 to 2033 (USD Million)
• 6.8. Digestive System Diseases
  • 6.8.1. Digestive system diseases market estimates and forecast 2021 to 2033 (USD Million)
• 6.9. Other (Respiratory Disease, Diabetes)
  • 6.9.1. Other (including clinical trial) market estimates and forecast 2021 to 2033 (USD Million)

Chapter 7. Drug Discovery Platforms Market: End Use Estimates & Trend Analysis

• 7.1. End Use Market Share, 2025 & 2033
• 7.2. Segment Dashboard
• 7.3. Global Drug Discovery Platforms Market by End use Outlook
• 7.4. Biopharmaceutical Companies
  • 7.4.1. Biopharmaceutical Companies market estimates and forecast 2021 to 2033 (USD Million)
• 7.5. Academic and Research Institutes
  • 7.5.1. Academic and Research Institites market estimates and forecast 2021 to 2033 (USD Million)
• 7.6. CROs/CDMO
  • 7.6.1. CROs/CDMO market estimates and forecast 2021 to 2033 (USD Million)

Chapter 8. Drug Discovery Platforms Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2025 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Regional Market Snapshot
• 8.4. Market Size, Forecasts, & Trends Analysis, 2021 to 2033:
• 8.5. North America
  • 8.5.1. U.S.
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 8.5.2. Canada
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 8.5.3. Mexico
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Market estimates and forecast, 2021 - 2033 (USD Million)
• 8.6. Europe
  • 8.6.1. UK
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 8.6.2. Germany
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 8.6.3. France
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 8.6.4. Italy
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 8.6.5. Spain
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 8.6.6. Sweden
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 8.6.7. Denmark
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 8.6.8. Norway
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Market estimates and forecast, 2021 - 2033 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Japan
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 8.7.2. China
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 8.7.3. India
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 8.7.4. South Korea
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 8.7.5. Thailand
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 8.7.6. Australia
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. Market estimates and forecast, 2021 - 2033 (USD Million)
• 8.8. Latin America
  • 8.8.1. Brazil
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 8.8.2. Argentina
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Market estimates and forecast, 2021 - 2033 (USD Million)
• 8.9. MEA
  • 8.9.1. South Africa
    • 8.9.1.1. Key country dynamics
    • 8.9.1.2. Regulatory framework
    • 8.9.1.3. Competitive scenario
    • 8.9.1.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 8.9.2. Saudi Arabia
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 8.9.3. UAE
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 8.9.4. Kuwait
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. Market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Key Company Market Share Analysis, 2025 (%)
• 9.4. Key Company Market Position Analysis, 2025
• 9.5. Company Profiles
  • 9.5.1. Schrodinger, Inc.
    • 9.5.1.1. Company overview
    • 9.5.1.2. Financial performance
    • 9.5.1.3. Product benchmarking
    • 9.5.1.4. Strategic initiatives
  • 9.5.2. Certara
    • 9.5.2.1. Company overview
    • 9.5.2.2. Financial performance
    • 9.5.2.3. Product benchmarking
    • 9.5.2.4. Strategic initiatives
  • 9.5.3. Optibrium Ltd
    • 9.5.3.1. Company overview
    • 9.5.3.2. Financial performance
    • 9.5.3.3. Product benchmarking
    • 9.5.3.4. Strategic initiatives
  • 9.5.4. Insilico Medicine
    • 9.5.4.1. Company overview
    • 9.5.4.2. Financial performance
    • 9.5.4.3. Product benchmarking
    • 9.5.4.4. Strategic initiatives
  • 9.5.5. Atomwise, Inc.
    • 9.5.5.1. Company overview
    • 9.5.5.2. Financial performance
    • 9.5.5.3. Product benchmarking
    • 9.5.5.4. Strategic initiatives
  • 9.5.6. XtalPi Holdings Limited
    • 9.5.6.1. Company overview
    • 9.5.6.2. Financial performance
    • 9.5.6.3. Product benchmarking
    • 9.5.6.4. Strategic initiatives
  • 9.5.7. Dassault Systemes SE
    • 9.5.7.1. Company overview
    • 9.5.7.2. Financial performance
    • 9.5.7.3. Product benchmarking
    • 9.5.7.4. Strategic initiatives
  • 9.5.8. Genedata AG
    • 9.5.8.1. Company overview
    • 9.5.8.2. Financial performance
    • 9.5.8.3. Product benchmarking
    • 9.5.8.4. Strategic initiatives
  • 9.5.9. Relay Therapeutics, Inc.
    • 9.5.9.1. Company overview
    • 9.5.9.2. Financial performance
    • 9.5.9.3. Product benchmarking
    • 9.5.9.4. Strategic initiatives
  • 9.5.10. Recursion Pharmaceuticals, Inc.
    • 9.5.10.1. Company overview
    • 9.5.10.2. Financial performance
    • 9.5.10.3. Product benchmarking
    • 9.5.10.4. Strategic initiatives
  • 9.5.11. Merck KGaA
    • 9.5.11.1. Company overview
    • 9.5.11.2. Financial performance
    • 9.5.11.3. Product benchmarking
    • 9.5.11.4. Strategic initiatives
  • 9.5.12. insitro Inc.
    • 9.5.12.1. Company overview
    • 9.5.12.2. Financial performance
    • 9.5.12.3. Product benchmarking
    • 9.5.12.4. Strategic initiatives